A systematic microdialysis study of dopamine transmission in the accumbens shell/core and prefrontal cortex after acute antipsychotics
The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Abstract
Rationale The only systematic in vivo studies comparing antipsychotic (AP) effects on nucleus accumbens (NAc) shell and core dopamine (DA) transmission are voltammetric studies performed in pargyline-pretreated, halothane-anaesthetized rats. Studies in freely moving rats not pretreated with pargyline are not available. This study was intended to fill this gap by the use of in vivo microdialysis in freely moving rats.Methods Male Sprague-Dawley rats were implanted with microdialysis probes in the NAc shell and core and medial prefrontal cortex (PFCX). The next day, rats were administered intravenously with two or three doses of APs, and dialysate DA was monitored in 10-min samples. Some rats were pretreated with pargyline (75 mg/kg i.p.) and after 1 h were given clozapine or risperidone.Results Clozapine, risperidone, quetiapine, raclopride, sulpiride and amisulpride increased DA preferentially in the NAc shell. Such preferential effect on shell DA was not observed after haloperidol, chlorpromazine and olanzapine. In contrast to voltammetric studies, a preferential effect on NAc core DA was not observed after any dose of AP. Pargyline pretreatment did not reduce but actually amplified the preferential effect of clozapine and risperidone on NAc shell DA.Conclusions Apart from raclopride and olanzapine, the APs with lower extrapyramidal effects could be distinguished from typical APs on the basis of their ability to preferentially stimulate DA transmission in the NAc shell. There was no relationship between stimulation of PFCX DA and atypical APs profile. The differences between this study and voltammetry studies were not attributable to pargyline pretreatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“McLarnon et al [36] examined quetiapine misuse among clients from a community-based methadone maintenance program, and found that 80% of participants reported a lifetime quetiapine use; of these, 21% reported taking quetiapine exclusively without a prescription.”
Citations
Cites
1 retracted
Li, H.-Z., Guo, J., Gao, J., Han, L.-P., Jiang, C.-M., Li, H.-X., Bai, S.-Z., Zhang, W.-H., Li, G.-W., Wang, L.-N., et al. (2011) · Journal of Biomedical Science · doi:10.1186/1423-0127-18-18 · Cited by 97
RetractedThe Rat Brain in Stereotaxic Coordinates
(1982) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 51,963 · cited 4×
“…two dialysis probes aimed at the NAc shell on one side and at the NAc core or at the PFCX on the other side, according to the rat brain atlas of Paxinos and Watson (1998) (uncorrected coordinates: PFCX, anterior=+3.5, L=±0.6, from bregma; verti- cal=5.0 from dura; NAc shell, A=+2.0, L=0.9,…”
InfluentialThe rat brain in stereotaxic coordinates
Palkovits, M. (1983) · Neuropeptides · doi:10.1016/0143-4179(83)90049-5 · Cited by 28,831
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 1×
“AP representative of different pharmacological categories were selected, namely haloperidol and chlorpromazine (high to intermediate D2R affinity and EPS liability), clozapine and quetiapine (low D2R, high to intermediate 5HT2A affinity and low EPS liability), amperozide (high 5HT2A, low D2R affinity and weak AP activ…”
Carlsson, A., & Lindqvist, M. (1963) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1963.tb01730.x · Cited by 2,148 · cited 1×
“Since the seminal studies by Carlsson (1974) (Carlsson and Lindqvist 1963), APs are known to increase all presynaptic indices of DA transmission, including synthesis, metabolism and release of DA and DA neuron firing activity (Anden et al.”
International Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,301 · cited 2×
“individual doses of intramuscular and oral APs utilized in the clinic (Gardner et al. 2010).”
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140 · cited 4×
“In the case of clozapine and quetiapine, fast dissociation (koff) fromD2 receptors (Kapur and Seeman 2001) would allow the reduction of receptor occupancy in parallel with the decrease of brain drug concentrations due to its distribution to peripheral compartments.”
InfluentialWise, R. A. (1996) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(96)80079-1 · Cited by 1,072
Receptor activity and turnover of dopamine and noradrenaline after neuroleptics
Andén, N.-E., Butcher, S. G., Corrodi, H., Fuxe, K., & Ungerstedt, U. (1970) · European Journal of Pharmacology · doi:10.1016/0014-2999(70)90006-3 · Cited by 1,026 · cited 1×
“Since the seminal studies by Carlsson (1974) (Carlsson and Lindqvist 1963), APs are known to increase all presynaptic indices of DA transmission, including synthesis, metabolism and release of DA and DA neuron firing activity (Anden et al. 1970; Bunney 1988; Imperato and Di Chiara 1985).”
Nucleus accumbens shell and core dopamine: differential role in behavior and addiction
Di Chiara, G. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00286-3 · Cited by 996 · cited 1×
“, Gambro Hospal, Italy) by a modification of the method described by Tanda and Di Chiara (1998).”
Cited by
Schifano, F., Chiappini, S., Corkery, J., & Guirguis, A. (2018) · Brain Sciences · doi:10.3390/brainsci8040073 · Cited by 93
Amato, D., Vernon, A. C., & Papaleo, F. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.09.027 · Cited by 92
Shin, J. H., Adrover, M. F., & Alvarez, V. A. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.0596-17.2017 · Cited by 70
“M2/4 mAChRs in CIN terminals depress the electrically evoked DA transients by inhibiting the release of ACh (Threlfell et al., 2010; Shin et al., 2015), M5 in DAN terminals potentiates the release of DA (Shin et al., 2015), and M4 mAChRs in D1 medium spiny neurons depresses the release of DA…”
BackgroundAddiction theory matters—Why there is no dependence on caffeine or antidepressant medication
Heinz, A., Daedelow, L. S., Wackerhagen, C., & Di Chiara, G. (2020) · Addiction Biology · doi:10.1111/adb.12735 · Cited by 45
Chiappini, S., & Schifano, F. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000814 · Cited by 44
Tanda, G. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4244-7 · Cited by 40
“( Tanda et al. 2015) Haloperidol, 0.006-0.025, IV INCREASE INCREASE (Tanda et al. 2015) Chlorpromazine, 0.”
BackgroundInfluentialSelf-citationEvoy, K. E., Teng, C., Encarnacion, V., Frescas, B., Hakim, J., Saklad, S. R., & Frei, C. R. (2019) · Substance Abuse Research and Treatment · doi:10.1177/1178221819844205 · Cited by 39
“Abuse-related event reports/Total events reported (%) 285/7320 (4) 356/8418 (4) 739/13961 (5) 1380/29699 (5)”
van den Bosch, R., Lambregts, B., Määttä, J. I., Hofmans, L., Papadopetraki, D., Westbrook, A., Verkes, R., Booij, J., & Cools, R. (2022) · Nature Communications · doi:10.1038/s41467-022-32679-1 · Cited by 35
Noradrenergic Source of Dopamine Assessed by Microdialysis in the Medial Prefrontal Cortex
Devoto, P., Sagheddu, C., Santoni, M., Flore, G., Saba, P., Pistis, M., & Gessa, G. L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.588160 · Cited by 27
Pharmacology profile of F17464, a dopamine D3 receptor preferential antagonist
Cosi, C., Martel, J., Auclair, A. L., Collo, G., Cavalleri, L., Heusler, P., Leriche, L., Gaudoux, F., Sokoloff, P., Moser, P. C., et al. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173635 · Cited by 27
Hendrickx, S., Uğur, D. Y., Yılmaz, I. T., Şener, E., Schepdael, A. V., Adams, E., Broeckhoven, K., & Cabooter, D. (2016) · Talanta · doi:10.1016/j.talanta.2016.09.053 · Cited by 24
Sagheddu, C., Pintori, N., Kalaba, P., Dragačević, V., Piras, G., Lubec, J., Simola, N., Luca, M. A. D., Lübec, G., & Pistis, M. (2020) · Biomolecules · doi:10.3390/biom10050779 · Cited by 22
“Vertical microdialysis probes were prepared with AN69 fibers (Hospal Dasco, Bologna, Italy), as previously described [39,40].”
MethodEffects of dopamine modulation on chronic stress-induced deficits in reward learning
Lamontagne, S. J., Wash, S. I. J., Irwin, S. H., Zucconi, K. E., & Olmstead, M. C. (2022) · Cognitive Affective & Behavioral Neuroscience · doi:10.3758/s13415-022-01001-3 · Cited by 18
“AMI preferentially stimulates DA transmission in the NAc, with negligible impact on mPFC DA release (Tanda et al., 2015).”
BackgroundAccess to the CNS: Biomarker Strategies for Dopaminergic Treatments
van den Brink, W. J., Palić, S., Köhler, I., & de Lange, E. C. M. (2018) · Pharmaceutical Research · doi:10.1007/s11095-017-2333-x · Cited by 20
“Short-term treatments with D2 receptor antagonists such as haloperidol, sulpiride, risperidone, olanzapine and clozapine have shown to stimulate the dopamine pathway (26,28), whereas administration of D2 receptor van den Brink, Palic, Köhler and de Lange”
BackgroundMcLean, S. L., Harte, M. K., Neill, J. C., & Young, A. M. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117704988 · Cited by 16
“, 2009), and clozapine, olanzapine and quietapine (Tanda et al., 2015) increase extracellular dopamine in male rat mPFC.”
BackgroundFitzgerald, N. D., & Day, J. J. (2024) · Addiction Neuroscience · doi:10.1016/j.addicn.2024.100191 · Cited by 17
Santis, M. D., Lian, J., Huang, X., & Deng, C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111944 · Cited by 16
“Previous acute and short-term studies into the effects of the potent D2 receptor antagonist risperidone revealed increased levels of DA production and transmission in the PFC and NAc of the adult rats [49,51].”
BackgroundMatsumoto, Y., Niwa, M., Mouri, A., Noda, Y., Fukushima, T., Ozaki, N., & Nabeshima, T. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4704-8 · Cited by 15
“…the extracellular levels of dopamine in PFc and NAc of rats (Bortolozzi et al. 2010; Kuroki et al. 1999; Li et al. 2005; Moghaddam and Bunney 1990; Tanda et al. 2015), our data are compatible with the previous reports that CLZ restores the changes in the overflow of dopamine in the PFc of mice…”
van den Brink, W. J., Elassaiss‐Schaap, J., Gonzalez‐Amoros, B., Harms, A. C., van der Graaf, P. H., Hankemeier, T., & de Lange, E. C. M. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.08.031 · Cited by 14
“Dopamine levels are increased in different brain regions after treatment with D2R antagonists (Tanda et al., 2015).”
BackgroundLee, M. R., Rohn, M. C. H., Zanettini, C., Coggiano, M. A., Leggio, L., & Tanda, G. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14101 · Cited by 15
Self-citationLoi, B., Sahai, M. A., Luca, M. A. D., Shiref, H., & Opacka‐Juffry, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00806 · Cited by 13
Nani, J. V. S., Lee, R. S., Yonamine, C. M., Sant’Anna, O. A., Juliano, M. A., Gadelha, A., Mari, J. D. J., & Hayashi, M. A. F. (2020) · Scientific Reports · doi:10.1038/s41598-020-75616-2 · Cited by 13
Region-specific effects of acute haloperidol in the human midbrain, striatum and cortex
Wächtler, C. O., Chakroun, K., Clos, M., Bayer, J., Hennies, N., Beaulieu, J., & Sommer, T. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.04.008 · Cited by 12
Liu, H., Zakiniaeiz, Y., Cosgrove, K., & Morris, E. D. (2017) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9779-7 · Cited by 10
“Microdialysis data of cortical DA (Narendran et al. 2014; Tanda et al. 2015; Jedema et al. 2014) can guide the creation of realistic simulations of extra-striatal DA responses.”
BackgroundDremencov, E., Lacinová, Ľ., Flik, G., Joost, H. A., F., T. I., & C., B. H. (2017) · General Physiology and Biophysics · doi:10.4149/gpb_2017039 · Cited by 8
Hersey, M., Bacon, A. K., Bailey, L. G., Lee, M. R., Chen, A. Y., Leggio, L., & Tanda, G. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15730 · Cited by 9
“A silastic catheter was implanted into the external jugular vein as previously described (Garces- Ramirez et al., 2011; Solinas et al., 2003; Solinas et al., 2006; Tanda et al., 2008; Tanda et al., 2015).”
MethodSelf-citationImportance of intervention timing in the effectiveness of antipsychotics
Liu, Y., Yang, Y.-Y., Wan, F.-J., & Tung, C. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.02.003 · Cited by 6
“Studies have revealed that OLA, when administered acutely, may stimulate the accumbal DA efflux (Koch et al., 2004; Tanda et al., 2015).”
Fos expression induced by olanzapine and risperidone in the central extended amygdala
Pinna, A., Costa, G., Contu, L., & Morelli, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172764 · Cited by 7
Synthetic Cannabinoids and Synthetic Cannabinoid-Induced Psychotic Disorders
Papanti, D., Fabrizio, S., & Orsolini, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804791-0.00009-4 · Cited by 5
Ma, J.-C., Che, X., Zhu, X.-N., Ren, A.-X., Hu, Y., Yang, C.-L., Xu, Z.-T., Li, Y., Wu, C., & Yang, J. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01321-9 · Cited by 3
“However, previous studies found that administration of the D2R antagonists Sulpiride and Haloperidol did not change the DA levels in the mPFC of rats [73, 74].”
Madhuranthakam, I. M., & Job, M. O. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.06.601793 · Cited by 2
“CNO is known to be converted to clozapine which can exert confounding pharmacological effects (Gomez et al., 2017; Ilg et al., 2018; MacLaren et al., 2016; Manvich et al., 2018; Neff et al., 2006; Padovan-Hernandez and Knackstedt, 2018; Rodd et al., 2022; Tanda et al., 2015; Ufer et al., 1999).”
BackgroundBukala, B. R., Vano, L. J., Carr, R., Cannon, A., Cummings, C., Davies, D., McCutcheon, R. A., Statton, B. K., Berry, A., Sedlacik, J., et al. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07173-x
Metadata
- Authors
- Tanda, G., Valentini, V., De Luca, M. A., Perra, V., Serra, G. P., & Di Chiara, G.
- Affiliations
- University of Cagliari (IT)
- Venue
- Psychopharmacology
- Published
- 2014-10-28
- Volume
- 232
- Issue
- 8
- Pages
- 1427-1440
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2038445102
- Cited by
- 33
- References
- 86
- Citations by year
- 2026: 1 · 2024: 3 · 2022: 3 · 2021: 1 · 2020: 6 · 2019: 4 · 2018: 2 · 2017: 10 · 2016: 3
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- Funders
- Ministero dell'Università e della Ricerca
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- antipsychotic drugs, dopamine signaling, nucleus accumbens shell, nucleus accumbens core, medial prefrontal cortex, clozapine, risperidone, quetiapine, raclopride, sulpiride, amisulpride, haloperidol, chlorpromazine, olanzapine, extrapyramidal symptoms, atypical antipsychotics, freely moving rats
- MeSH terms
- Animals, Chlorpromazine, Clozapine, Dopamine, Haloperidol, Male, Nucleus Accumbens, Time Factors, Antipsychotic Agents, Rats, Sprague-Dawley, Prefrontal Cortex, Microdialysis, Risperidone, Raclopride, Rats, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.